Next Article in Journal
Characterization of Erysiphe necator-Responsive Genes in Chinese Wild Vitis quinquangularis
Next Article in Special Issue
Effects of Sorafenib on C-Terminally Truncated Androgen Receptor Variants in Human Prostate Cancer Cells
Previous Article in Journal
Maternal Phylogeny of a Newly-Found Yak Population in China
Previous Article in Special Issue
The Dual Role of Inflammation in Colon Carcinogenesis
Int. J. Mol. Sci. 2012, 13(9), 11471-11496; doi:10.3390/ijms130911471

Personalized Targeted Therapy for Lung Cancer

1 Department of Medicine, University of Chicago, Chicago, IL 60637, USA 2 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA 3 Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China
* Author to whom correspondence should be addressed.
Received: 7 August 2012 / Revised: 5 September 2012 / Accepted: 7 September 2012 / Published: 13 September 2012
(This article belongs to the Special Issue Advances in Molecular Oncology (special issue))
View Full-Text   |   Download PDF [569 KB, uploaded 19 June 2014]   |   Browse Figures


Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical characterizations, prognosis, response and tolerance to treatment. Personalized medicine refers to the use of markers to predict which patient will most likely benefit from a treatment. In lung cancer, the well-developed epidermal growth factor receptor (EGFR) and the newly emerging EML4-anaplastic lymphoma kinase (ALK) are important therapeutic targets. This review covers the basic mechanism of EGFR and EML4-ALK activation, the predictive biomarkers, the mechanism of resistance, and the current targeted tyrosine kinase inhibitors. The efficacy of EGFR and ALK targeted therapies will be discussed in this review by summarizing the prospective clinical trials, which were performed in biomarker-based selected patients. In addition, the revolutionary sequencing and systems strategies will also be included in this review since these technologies will provide a comprehensive understanding in the molecular characterization of cancer, allow better stratification of patients for the most appropriate targeted therapies, eventually resulting in a more promising personalized treatment. The relatively low incidence of EGFR and ALK in non-Asian patients and the lack of response in mutant patients limit the application of the therapies targeting EGFR or ALK. Nevertheless, it is foreseeable that the sequencing and systems strategies may offer a solution for those patients.
Keywords: ALK; biomarker; EGFR; lung cancer; next-generation sequencing ALK; biomarker; EGFR; lung cancer; next-generation sequencing
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Wu, K.; House, L.; Liu, W.; Cho, W.C. Personalized Targeted Therapy for Lung Cancer. Int. J. Mol. Sci. 2012, 13, 11471-11496.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert